preprint
Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
Fecha
2021Registro en:
10.1101/2021.03.31.21254494
1058-4838
Autor
Bueno Ramírez, Susan
Abarca Villaseca, Katia
González Adonis, Pablo Andrés
Gálvez Arriagada, Nicolás Marcelo Salvador
Soto Ramírez, Jorge Andrés
Duarte Peñaloza, Luisa Fernanda
Schultz Lombardic, Bárbara M.
Pacheco, Gaspar A.
González Carreño, Liliana Andrea
Vázquez, Yaneisi
Ríos Raggio, Mariana
Melo González, Felipe
Rivera Pérez, Daniela
Iturriaga, Carolina
Urzúa Acevedo, Marcela del Pilar
Domínguez De Landa, María Angélica
Andrade Parra, Catalina Andrea
Berríos Rojas, Roslye
Canedo Marroquín, Giselda
Covián, Camila
Institución
Resumen
The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. The rapid development of safe and protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical trials are ongoing with CoronaVac in Brazil, Indonesia, Turkey, and Chile. This article reports the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and older enrolled in the phase 3 Clinical Trial held in Chile.